Patents Represented by Attorney, Agent or Law Firm David S. Harper
  • Patent number: 6703363
    Abstract: The present invention provides recombinant laminin 5, methods for making recombinant laminin 5, cells that express recombinant laminin 5, and methods for using the recombinant laminin 5 to accelerate wound healing, and to promote cell attachment and migration.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: March 9, 2004
    Assignee: BioStratum, Inc.
    Inventor: Ariel Boutaud
  • Patent number: 6671624
    Abstract: The present invention provides systems, methods, and screens for an optical system analysis of cells to rapidly determine the distribution, environment, or activity of fluorescently labeled reporter molecules in cells for the purpose of screening large numbers of compounds for those that specifically affect particular biological functions. The invention involves providing cells containing fluorescent reporter molecules in an array of locations and scanning numerous cells in each location with a high magnification fluorescence optical system, converting the optical information into digital data, and utilizing the digital data to determine the distribution, environment or activity of the fluorescently labeled reporter molecules in the cells. The array of locations may be an industry standard 96 well or 384 well microtiter plate or a microplate which is a microplate having a cells in a micropaterned array of locations.
    Type: Grant
    Filed: November 27, 2000
    Date of Patent: December 30, 2003
    Assignee: Cellomics, Inc.
    Inventors: R. Terry Dunlay, D. Lansing Taylor, Albert H. Gough, Kenneth A. Giuliano
  • Patent number: 6638907
    Abstract: The present invention provides substantially purified laminin 8, methods for making recombinant laminin 8, cells that express recombinant laminin 8, and methods for using the recombinant laminin 8 to accelerate the healing of injuries to vascular tissue and tissue of mesenchymal origin, and to promote cell attachment and migration.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: October 28, 2003
    Assignee: BioStratum, Inc.
    Inventors: Jarrko Kortesmaa, Karl Tryggvason
  • Patent number: 6632790
    Abstract: The present invention provides substantially purified laminin 2, methods for making recombinant laminin 2, cells that express recombinant laminin 2, and methods for using the substantially purified laminin 2 to accelerate peripheral nervous system nerve regeneration, and to promote cell attachment and migration.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: October 14, 2003
    Assignee: University of Medicine and Dentistry of New Jersey
    Inventor: Peter Yurchenco
  • Patent number: 6620591
    Abstract: The invention relates to an optical system for determining the distribution, environment, or activity of fluorescently labeled reporter molecules in cells for the purpose of screening large numbers of compounds for specific biological activity. The invention involves providing cells containing fluorescent reporter molecules in an array of locations and scanning numerous cells in each location with a fluorescent microscope, converting the optical information into digital data, and utilizing the digital data to determine the distribution, environment or activity of the fluorescently labeled reporter molecules in the cells. The array of locations may be an industry standard 96 well or 384 well microtiter plate or a microplate which is a microplate having a cells in a micropaterned array of locations. The invention includes apparatus and computerized method for processing, displaying and storing the data.
    Type: Grant
    Filed: April 16, 1999
    Date of Patent: September 16, 2003
    Assignee: Cellomics, Inc.
    Inventors: R. Terry Dunlay, D. Lansing Taylor
  • Patent number: 6610852
    Abstract: The present invention provides novel compounds, pharmaceutical compositions, methods, and kits for inhibiting the conversion of Amadori compounds to post Amadori advanced glycation endproducts, and for treating and preventing chronic tissue damage and diabetic complication.
    Type: Grant
    Filed: October 19, 2001
    Date of Patent: August 26, 2003
    Assignee: Kansas University Medical Center
    Inventors: Raja Khalifah, Aaron Ashley Booth
  • Patent number: 6579969
    Abstract: The present invention provides isolated nucleic acid sequences and expression vectors encoding the Goodpasture antigen binding protein (GPBP), substantially purified GPBP, antibodies against GPBP, and methods for detecting GPBP.
    Type: Grant
    Filed: February 24, 2000
    Date of Patent: June 17, 2003
    Inventor: Juan Saus
  • Patent number: 6573039
    Abstract: The invention relates to an optical system for determining the distribution, environment, or activity of fluorescently labeled reporter molecules in cells for the purpose of screening large numbers of compounds for specific biological activity. The invention involves providing cells containing fluorescent reporter molecules in an array of locations and scanning numerous cells in each location with a fluorescent microscope, converting the optical information into digital data, and utilizing the digital data to determine the distribution, environment or activity of the fluorescently labeled reporter molecules in the cells. The array of locations may be an industry standard 96 well or 384 well microtiter plate or a microplate which is a microplate having a cells in a micropaterned array of locations. The invention includes apparatus and computerized method for processing, displaying and storing the data.
    Type: Grant
    Filed: August 29, 2000
    Date of Patent: June 3, 2003
    Assignee: Cellomics, Inc.
    Inventors: R. Terry Dunlay, D. Lansing Taylor
  • Patent number: 6566335
    Abstract: The present invention provides improved methods, kits, and pharmaceutical compositions for increasing white blood cell survival following chemotherapy, and mobilizing hematopoietic progenitor cells from bone marrow into peripheral blood, comprising the administration of an effective amount of angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II (AII), AII analogues, AII fragments or analogues thereof or AII AT2 type 2 receptor agonists.
    Type: Grant
    Filed: November 20, 2000
    Date of Patent: May 20, 2003
    Assignee: University of Southern California
    Inventors: Kathleen E. Rodgers, Gere DiZerega
  • Patent number: 6548263
    Abstract: The present invention describes novel methods for making a substrate for selective cell patterning, and the substrates themselves, wherein the method comprises contacting reactive hydroxyl groups on the surface of a substrate with a hydroxyl-reactive bifunctional molecule to form a monolayer, and using stencils to deposit cell repulsive or cell adhesive moieties in controlled locations on the cell culture substrate. Methods comprising selective differentiation of stem cells to create tissue specific and organ-specific cell substrates, as well as the cell substrates themselves are also provided.
    Type: Grant
    Filed: March 31, 2000
    Date of Patent: April 15, 2003
    Assignee: Cellomics, Inc.
    Inventors: Ravi Kapur, Terri Adams
  • Patent number: 6498138
    Abstract: The present invention provides methods, improved cell culture medium and kits for accelerating the generation of tissue equivalents, and for improving the quality of tissue equivalents, by growth in the presence of angiotensinogen, AI, AI analogues, Al fragments and analogues thereof, AII, AI analogues, AII fragments and analogues thereof and/or AII AT2 type 2 receptor agonists.
    Type: Grant
    Filed: March 11, 1999
    Date of Patent: December 24, 2002
    Assignee: University of Southern California
    Inventors: Kathleen E. Rodgers, Gere DiZerega
  • Patent number: 6498140
    Abstract: The instant invention provides methods and kits for inhibiting angiogenesis, tumor growth and metastasis, and endothelial cell interactions with the extracellular matrix, involving contacting the tumor or animal tissue with at least one isolated type IV collagen NC1 &agr; chain monomer. In a specific embodiment of the invention, the isolated domain of type IV collagen comprises the NC1 (&agr;1), (&agr;2), (&agr;3), or (&agr;6) chain monomer, or protein constructs having substantially the same structure as the NC1 (&agr;1), (&agr;2), (&agr;3), or (&agr;6) chain monomer.
    Type: Grant
    Filed: June 7, 2000
    Date of Patent: December 24, 2002
    Assignee: University of Kansas Medical Center
    Inventors: Billy G. Hudson, Michael P. Sarras, Jr.
  • Patent number: 6482800
    Abstract: The present invention provides methods and kits for increasing blood flow to isehemic tissue, comprising the administration of an effective amount of angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II (AII), AII analogues, AII fragments or analogues thereof or AII AT2 type 2 receptor agonists.
    Type: Grant
    Filed: September 8, 2000
    Date of Patent: November 19, 2002
    Assignee: The University of Southern California
    Inventors: Kathleen E. Rodgers, Gere DiZerega
  • Patent number: 6475988
    Abstract: The present invention provides improved methods, kits, and pharmaceutical compositions for increasing white blood cell survival following chemotherapy, and mobilizing hematopoietic progenitor cells from bone marrow into peripheral blood, comprising the administration of an effective amount of angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II (AII), AII analogues, AII fragments or analogues thereof or AII AT2 type 2 receptor agonists.
    Type: Grant
    Filed: May 10, 1999
    Date of Patent: November 5, 2002
    Assignee: University of Southern California
    Inventors: Kathleen E. Rodgers, Gere DiZerega
  • Patent number: 6472400
    Abstract: The instant invention provides compositions and methods for modeling post-Amadori AGE formation and the identification and characterization of effective inhibitors of post-Amadori AGE formation, and such identified inhibitor compositions.
    Type: Grant
    Filed: May 28, 1999
    Date of Patent: October 29, 2002
    Assignee: University of Kansas Medical Center
    Inventors: Billy G. Hudson, Parvin Todd, Raja Gabriel Khalifah, Aaron Ashley Booth
  • Patent number: 6472411
    Abstract: The instant invention provides compositions and methods for modeling post-Amadori AGE formation and the identification and characterization of effective inhibitors of post-Amadori AGE formation, and such identified inhibitor compositions.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: October 29, 2002
    Assignee: University of Kansas Medical Center
    Inventors: Billy G. Hudson, Parvin Todd, Raja Gabriel Khalifah, Aaron Ashley Booth
  • Patent number: 6455501
    Abstract: Methods and compositions based on chemical analogs of angiotensin II and analogs of angiotensin II fragments useful for accelerating wound healing in mammals.
    Type: Grant
    Filed: October 27, 2000
    Date of Patent: September 24, 2002
    Assignee: University of Southern California
    Inventors: Kathleen E. Rodgers, Gere S. DiZerega
  • Patent number: 6455500
    Abstract: The present invention provides methods and kits for mitigating radiation induced tissue damage, improving the effectiveness of radiation therapy, to support bone marrow transplantation, and promoting megakaryocyte production and mobilization and platelet production, each method comprising the administration of an effective amount of angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II (AII), AII analogues, AII fragments or analogues thereof or AII AT2 type 2 receptor agonists.
    Type: Grant
    Filed: March 8, 1999
    Date of Patent: September 24, 2002
    Assignee: University of Southern California
    Inventors: Kathleen E. Rodgers, Gere DiZerega
  • Patent number: 6448222
    Abstract: The instant invention demonstrates that the 7S domain of type IV collagen disrupts cell aggregation and tissue development. Structural changes in mesoglea, inhibition of cell proliferation, and changes in cell differentiation patterns accompanies the blockage of cell aggregates which indicate that blockage may be due to alterations in mesoglea (extracellular matrix) structure with accompanying effects on cell behavior. Type IV collagen has a critical role in the initial formation of mesoglea and that perturbation of mesoglea formation effects cell division, cell differentiation, and morphogenesis.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: September 10, 2002
    Assignee: University of Kansas Medical Center
    Inventors: Michael P. Sarras, Jr., Billy G. Hudson
  • Patent number: 6444646
    Abstract: Angiotensin II Type 2 receptor agonists (AT2 receptor subtype agonists) are useful in accelerating wound healing. These compounds form the basis of compositions useful for accelerating wound healing, in which the active agent is present in an amount effective to accelerate wound healing. Preferably, the compositions are in the form of matrical or micellar solutions.
    Type: Grant
    Filed: February 14, 2000
    Date of Patent: September 3, 2002
    Assignee: University of Southern California
    Inventors: Kathleen Elizabeth Rodgers, Gere Stodder Dizerega